Supplemental Table S4: YVL-BR specific and GLC-BM specific TRAV and TRBV dominant motifs in persistent, non-persistent and *de novo* clonotypes.

A. YVL-BR specific TRAV (persistent clonotypes)

T cell receptor:						Valpha						
Motif sequence:					Per	rsistent "VKDTDK	" (9-mer)					
Sample name:		E	E1603			E1	632			E1	655	
Phase of infection:	A	IM	C	ONV	A	MM	CC	VNC	AIM		CONV	
Frequency of all copies (reads):	32.37% (1,238	,327/3,824,852)	42.29% (1,426	6,296/3,372,293)	12.66% (1,533,671/12,114,592)		15.87% (1,529,404/9,637,298)		81.82% (328,595/401,597)		1.08% (81,139/ 7,472,18	
Frequency of all unique clonotypes:	21.95% (36/164)		21.95% (36/164)		15.71%	(71/452)	15.71%	(71/452)	6.21% (25/402)		6.21%	25/402)
Family usage (%):	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ
(% of usage of all other families detected for this sample)	AV8-1 (97.22%)	AJ34-1 (94.44%)	AV8-1 (97.22%)	AJ34-1 (94.44%)	AV8-1 (95.77%)	AJ34-1 (88.73%)	AV8-1 (95.77%)	AJ34-1 (88.73%)	AV8-1 (80%)	AJ34-1 (76%)	AV8-1 (80%)	AJ34-1 (76%)
	AV12-2 (2.78%)	AJ45-1 (5.56%)	AV12-2 (2.78%)	AJ45-1 (5.56%)	AV25 (1.4%)	AJ32-1 (2.81%)	AV25 (1.4%)	AJ32-1 (2.81%)	AV12-2 (16%)	AJ50-1 (8%)	AV12-2 (16%)	AJ50-1 (8%)
					AV14-1 (1.4%)	AJ30-1 (5.66%)	AV14-1 (1.4%)	AJ30-1 (5.66%)	AV21-1 (4%)	AJ32-1 (4%)	AV21-1 (4%)	AJ32-1 (4%)
					AV3-1 (1.4%)	AJ59 (1.4%)	AV3-1 (1.4%)	AJ59-1 (1.4%)		AJ26-1 (4%)		AJ26-1 (4%)
						AJ37 (1.4%)		AJ37-1 (1.4%)		AJ3-1 (8%)		AJ3-1 (8%)

B. YVL-BR specific TRAV (non-persistent clonotypes)

T cell receptor:		Valpha Non-Persistent "VKDTDK" (9-mer)												
Motif sequence:						Non-Persistent "	/KDTDK" (9-mer)							
Sample name:		E16	503			E16	32			E16	55			
Phase of infection:	-	AIM	CO	NV	Α	MIM	CC	ONV	4	MM	CONV			
Frequency of all copies (reads):	8.02% (147,-	408/1,835,880)	not a	pplied	5.14% (185,1	75/3,602,802)	not applied		5.74% (792,2	04/13,797,945)	not applied			
Frequency of all unique clonotypes:	8.09% (159/1965)	not a	pplied	4.71% (2	219/4,641)	not a	pplied	2.17% (196/9,021)	not ap	plied		
Family usage (%):	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ	TRAV TRAJ		TRAV	TRAJ	TRAV	TRAJ		
(% of usage of all other families detected for this sample)			not a	pplied	AV8-1 (82.19%)	AJ34-1 (90.84%)	not applied		AV8-1 (91.84%)	AJ34-1 (92.86%)	not ap	plied		
	AV12-2 (13.20%)	AJ32 (1.88%)			AV12 (11.87%)	AJ46 (1.37%)			AV12 (2.04%)	AJ30 (1.02%)				
	AV3 (1.88%) AJ30 (1.25%)				AV21-1 (2.28%)	AJ32 (1.37%)			AV39-1 (1.02%)	AJ20 (1.02%)				
	AV6 (1.25%)	AJ39 (0.62%)			AV14-1 (1.37%)	AJ31-1 (1.37%)			AV21 (1.02%)	AJ10 (1.02%)				
	AV25-1 (0.62%)	AJ20 (1.24%)			AV3 (0.91%)	AJ39-1 (0.91%)			AV5 (1.02%)	AJ59 (0.51%)				
	AV21-1 (0.62%)				AV23-1 (0.45%)	AJ37-1 (0.91%)			AV3 (1.02%)	AJ46 (0.51%)				
					AV16-1 (0.45%)	AJ20 (0.91%)			AV29 (0.51%)	AJ37 (0.51%)				
					AV6 (0.45%)	AJ3 (0.91%)			AV23 (0.51%)	AJ36 (0.51%)				
						AJ44 (0.45%)			AV19 (0.51%)	AJ32 (0.51%)				
						AJ27-1 (0.45%)			AV13 (0.51%)	AJ26-1 (0.51%)				
						AJ14-1 (0.45%)				AJ23 (1.2%)				

C. YVL-BR specific TRAV (*de novo* clonotypes)

T cell receptor:							/alpha					
Motif sequence:						De novo "	VKNTDK" (9-mer)					
Sample name:		E	1603				E1632			E	1655	
Phase of infection:	Α	IM	C	ONV	AI	Μ	C	ONV	Α	IM	CONV	
Frequency of all copies (reads):	not applied 0.0035% (65/1,835			65/1,835,880)	not ap	plied	0.00094%	(34/3,602,802)	not ap	oplied	0.00025% (34/13797945)	
Frequency of all unique clonotypes:	not applied		0.4% (8/1,965)		not applied		0.24% (11/4,641)		na		0.055% (5/9,021)	
Family usage (%):	TRAV TRAJ		TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ
(% of usage of all other families detected for this sample)	not a	pplied	AV8-1 (100%)	AJ34-1(100%)	not ap	plied	AV8-1 (100%)	AJ34-1 (90.9%)	not a	oplied	AV8-1 (100%)	AJ34-1(100%)
								AJ37-1 (9.1%)				

D. YVL-BR specific TRBV (persistent clonotypes)

T cell receptor:						Vbeta						
Motif sequence:					Pers	sistent "SALLGX"	(13-mer)					
Sample name:			E1603			E16	632			E1	655	
Phase of infection:	4	AIM	CO	NV	AIM		CC	DNV	Α	Μ	CO	NV
Frequency of all copies (reads):	26.71% (5,002,	042 / 18,722,687)	23.65% (3,472,0	87/14,679,574)	not found		not found		not f	ound	not fo	ound
Frequency of all unique clonotypes:	15.55%	(105/675)	15.55% (105/675)	not found		not	found	not f	ound	not found	
Family usage (%):	TRBV			TRBJ	TRBV	TRBJ	TRBV	TRBJ	TRBV	TRBJ	TRBV	TRBJ
(% of usage of all other families detected for this sample)	BV6-5 (86.66%)			BJ2-3 (100%)	not found	not found	not found	not found	not found	not found	not found	not found
	BV28-1 (1.9%)											
	BV27-1 (1.9%)		BV27-1 (1.9%)									
	BV3un (1.9%)		BV3 (1.9%)									
	BV25-1 (0.95%)		BV25-1 (0.95%)									
	BV21-1 (0.95%)		BV21-1 (0.95%)									
	BV19-1 (0.95%)		BV19-1 (0.95%)									
	BV13-1 (0.95%)		BV13-1 (0.95%)									
	BV12 (0.95%)		BV12 (0.95%)									
	BV10-1 (0.95%)		BV10-1 (0.95%)									
	BV7-3 (0.95%)		BV7-3 (0.95%)									
	BV2 (0.95%)		BV2 (0.95%)									

E. YVL-BR specific TRBV (non-persistent clonotypes)

T cell receptor:						Vb	eta					
Motif sequence:						Non Persistent "S	ALLGX" (13-mer)					
Sample name:		E1	603			E1	632			E16	55	
Phase of infection:	1	AIM	CC	VNC	A	IM	CC	ONV	A	IM	COI	4V
Frequency of all copies (reads):	1.06% (28,2	269/2,665,368)	not a	applied	not	ound	not a	pplied	not f	ound	not ap	plied
Frequency of all unique clonotypes:	12.27%	(609/4,960)	not a	applied	not	ound	not a	pplied	not f	ound	not ap	plied
Family usage (%):	TRBV	TRBJ	TRBV	TRBJ	TRBV	TRBJ	TRBV TRBJ		TRBV TRBJ		TRBV	TRBJ
(% of usage of all other families detected for this sample)	sage of all other families detected for this sample) BV6 (94.74%) BJ2 (99.84%)		not a	applied	not found	not found	not applied		not found	not found	not ap	plied
	BV7 (2.45%)	BJ1 (0.16%)										
	BV12 (0.65%)											
	BV27-1 (0.33%)											
	BV24 (0.33%)											
	BV11 (0.33%)											
	BV5 (0.33%)											
	BV2 (0.33%)											
	BV14 (0.16%)											
	BV4 (0.16%)											
	BV3 (0.16%)											

F. YVL-BR specific TRBV (*de novo* clonotypes)

T cell receptor:		Vbeta De Novo "SALLGX" (13-mer)												
Motif sequence:						De Novo "SA	ALLGX" (13-mer)							
Sample name:		E	1603			E	1632			E,	1655			
Phase of infection:	Α	IM	CC	ONV	A	IM	(CONV	AI	N	CC	DNV		
Frequency of all copies (reads):	not ap	pplied	0.042% (2,4	94/5,909,194)	not applied 11.64% (861,364/7,396,900)		1,364/7,396,900)	not applied		not f	ound			
Frequency of all unique clonotypes:	not a	pplied	11.72% (2	244/2,081)	not ap	not applied		(145/3,368)	not app	olied	not found			
Family usage (%):	TRBV	TRBJ	TRBV	TRBJ	TRBV	TRBJ	TRBV TRBJ		TRBV	TRBJ	TRBV	TRBJ		
(% of usage of all other families detected for this sample)	not a	pplied	BV6 (97.95%)	BJ2 (99.59%)	not applied		BV6 (82.06%)	BJ2 (100%)	not applied		not found	not found		
			BV27 (0.82%)	BJ1 (0.41%)			BV10 (3.45%)							
			BV28-1 (0.41%)				BV7-6 (2.76%)							
			BV10 (0.41%)				BV28-1 (2.07%)					1		
			BV9 (0.41%)				BV27-1 (1.38%)							
							BV13 (1.38%)							
							BV3 (1.38%)							
							BV25 (0.69%)							
							BV24 (0.69%)							
							BV19-1 (0.69%)					1		
							BV12 (0.69%)					1		
							BV11 (0.69%)					1		
							BV5 (0.69%)					1		
							BV2 (1.38%)							

G. GLC-BM specific TRAV (persistent clonotypes)

T cell receptor:						Va	lpha					
Motif sequence:						Persistent "E	DNNA" (9-mer)					
Sample name:		E1	603			E1	632			E1	E1655	
Phase of infection:	A	IM	C	VNC	A	MM	CC	ONV	A	IM	CONV	
Frequency of all copies (reads):	12.45% (603,951/4,847,739) 27.39% (1573,133/5,742,713) 24.57% (29/118) 24.57% (29/118)			1.55% (181,2	1.55% (181,290/1,1676,908) 1.55% (181,290/1,1676,908)			0.91% (133,33	31/14,630,436)	1.77% (198,068/11,163,342		
Frequency of all unique clonotypes:	24.57%	24.57% (29/118) 24.57% (29/118)		7.87%	(26/330)	7.87% (26/330)		2.6% (21/810)		2.6% (21/810)		
Family usage (%):	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ
(% of usage of all other families detected for this sample)	AV5-1(96.55%)	AJ31-1 (100%)	AV5-1(96.55%)	AJ31-1 (100%)	AV5-1 (61.54%)	AJ31-1 (96.15%)	AV5-1 (61.54%)	AJ31-1 (96.15%)	AV5-1 (80.95%)	AJ31-1 (95.23%)	AV5-1 (80.95%)	AJ31-1 (95.23%)
	AV23-1 (3.44%)		AV23-1 (3.44%)		AV13-1 (15.38%)	AJ13 (3.84%)	AV13-1 (15.38%)	TCRAJ13: 3.846%	AV13-1 (14.28%)	AJ13-1 (4.76%)	AV13-1 (14.28%)	AJ13-1 (4.76%)
					AV14-1 (7.69%)		AV14-1 (7.69%)		AV23-1 (4.77%)		AV23-1 (4.77%)	
					AV9-1 (7.69%)		AV9-1 (7.69%)					
					AV6 (7.69%)		AV6 (7.69%)					

H. GLC-BM specific TRAV (*de novo* clonotypes)

T cell receptor:						Va	lpha					
Motif sequence:						De Novo "E	LDGQ" (9-mer)					
Sample name:		E	1603			E	1632			E	1655	
Phase of infection:	Α	IM	C	ONV	AIM		CC	VNC	A	IM	CC	NV
Frequency of all copies (reads):	not a	pplied	10.64% (1,243	3,532/11,680,562)	not applied 0.0012% (177/14,259,876)		7/14,259,876)	not a	pplied	not f	ound	
Frequency of all unique clonotypes:	not applied		8.31% (217/2,609)		not applied		0.03%	(1/3,292)	not a	pplied	not found	
Family usage (%):	TRAV TRAJ		TRAV	TRAJ	TRAV	TRAJ	TRAV	TRAJ	TRAV TRAJ		TRAV	TRAJ
(% of usage of all other families detected for this sample)	not applied AV5-1 (94		AV5-1 (94%)	AJ16-1 (99.54%)	not a	pplied	AV5-1 (100%)	AJ16-1 (100%)	not a	pplied	not found	not found
			AV23-1 (1.38%)	AJ39-1 (0.46%)								
			AV13-1 (1.38%)									
			AV19-1 (0.92%)									
			AV14-1 (0.92%)									
			AV38-1 (0.46%)									
			AV9-1 (0.92%)									

I. GLC-BM specific TRBV (persistent clonotypes)

T cell receptor:		Vbeta Persistent "SQSPGG" (11-mer)											
Motif sequence:						Persistent "SC	SPGG" (11-mer)						
Sample name:		E1	603			E1	1632			E	1655		
Phase of infection:	Α	IM	CC	ONV	A	IM	CC	DNV	A	IM	CC	VNC	
Frequency of all copies (reads):	not f	ound	not f	found	31.22% (5,349,	199/17,132,769)	4.26% (214,4	40/5,029,504)	47.86% (4,665	,421/9,746,758)	8254039 / 15050	633 = 54.841806%	
Frequency of all unique clonotypes:	not f	ound	not f	found	5.35%	(19/355)	5.35%	(19/355)	22.95%	(202/880)	202 / 880 =	22.954545%	
Family usage (%):	TRBV	TRBJ	TRBV	TRBJ	TRBV	TRBJ	TRBV	TRBJ	TRBV	TRBJ	TRBV	TRBJ	
(% of usage of all other families detected for this sample)	not found	not found	not found	not found	BV14-1 (47.36%)	BJ2-4 (100%)	BV14-1 (47.36%)	BJ2-4 (100%)	BV14-1 (57.92%)	BJ2-5 (100%)	BV14-1 (57.92%)	BJ2-5 (100%)	
					BV5-1 (10.52%)		BV5-1 (10.52%)		BV7.2 (8.91%)		BV7.2 (8.91%)		
					BV27 (5.26%)		BV27 (5.26%)		BV9-1 (4.45%)		BV9-1 (4.45%)		
			BV18 (5.26%)		BV18-1 (5.26%)		BV6 (4.45%)		BV6 (4.45%)				
			BV12 (5.26%)		BV12 (5.26%)		BV4-1 (3.46%)		BV4-1 (3.46%)				
					BV11 (5.26%)		BV11 (5.26%)		BV27 (2.47%)		BV27 (2.47%)		
					BV9-1 (5.26%)		BV9-1 (5.26%)		BV25 (2.47%)		BV25 (2.47%)		
					BV7-2 (5.26%)		BV7-2 (5.26%)		BV23 (2.47%)		BV23 (2.47%)		
					BV6 (5.26%)		BV6 (5.26%)		BV21 (2.47%)		BV21 (2.47%)		
					BV3-1 (5.26%)		BV3-1 (5.26%)		BV12 (2.47%)		BV12un (2.47%)		
									BV11 (2.47%)		BV11 (2.47%)		
									BV3 29.47%)		BV3 29.47%)		
									BV2 (1.48%)		BV2 (1.48%)		
									BV13 (0.99%)		BV13 (0.99%)		
									BV28 (0.49%)		BV28 (0.49%)		
									BV10 (0.49%)		BV10 (0.49%)		

J.GLC-BM specific TRBV (non-persistent clonotypes)

T cell receptor:						Vb	eta					
Motif sequence:						Non Persistent	"SARD" (11-mer)					
Sample name:		E10	603			E1	632			E1(655	
Phase of infection:	A	IM	CC	NV	A	IM	CC	ONV	A	MIM	CONV	
Frequency of all copies (reads):	4.78% (488,79	98 / 10,224,655)	not a	pplied	3.03% (114,3	41 / 3,769,869)	not a	applied	0.95% (19,20	06 / 2,020,587)	not a	pplied
Frequency of all unique clonotypes:	13.84% (3	13.84% (371 / 2,681) not applied				3.66% (148 / 4,043) not applied			2.54% (1	40 / 5,508)	not a	pplied
Family usage (%):	TRBV	TRBJ	TRBV	TRBV TRBJ		TRBV TRBJ		TRBJ	TRBV	TRBJ	TRBV	TRBJ
(% of usage of all other families detected for this sample)	BV20 (99.46%)	BJ1-2 (99.73%)	not applied B		BV20 (98.65%)	BJ01 (97.97%)	not a	applied	BV20 (99.28%)	BJ1-3 (99.28%)	not a	pplied
	BV29-1 (0.54%)	BJ2 (0.27%)			BV29-1 (1.35%)	BJ2 (2.03%)			BV29-1 (0.72%)	BJ2 (0.71%)		

K. GLC-BM specific TRBV (*de novo* clonotypes)

					v	beta					
					De Novo "S	ARD" (11-mer)					
	E	1603			E	1632				E1655	
A	IM	CC	NV	A	IM	CO	NV	AIM		CONV	
not applied		4.9% (517,874/10,580,372)		not a	pplied	10.14% (948,7	733/9,348,647)	not a	oplied	0.012% (666	6/ 5,575,518)
not applied		8.41% (213/2,532)		not applied		2.3% (13	32/5,764)	not applied		1.4% (73/5,207)	
TRAV	TRAJ			TRAV	TRAJ	TRBV	TRBJ	TRAV	TRAJ	TRBV	TRBJ
not a	not applied BV20-1 (98.59%) BJ1-3 (99.53%		BJ1-3 (99.53%)	not a	pplied	BV20-1 (98.48%)	BJ1 (89.39%)	not a	oplied	BV20-1 (100%)	BJ1 (95.89%)
		BV29-1(1.41%)	BJ2-3 (0.47%)			BV29-1 (1.52%)	BJ2-3 (10.6%)				BJ2-1 (4.11%)
	not a not a TRAV	AIM not applied not applied TRAV TRAJ	not applied 4.9% (517,87 not applied 8.41% (2 TRAV TRAJ TRAV TRBV not applied BV20-1 (98.59%)	AIM CONV not applied 4.9% (517,874/10,580,372) not applied 8.41% (2132,532) TRAV TRJ TRAV TRBJ not applied BV20-1 (98.59%) BJ1-3 (99.53%)	AIM CONV AI not applied 4.9% (517.874/10,580,372) not ap not applied 8.41% (213/2,532) not ap TRAV TRAJ TRBJ TRAV not applied BV20-1 (98.59%) BJ1-3 (99.53%) not ap	De Novo "S E1603 E' AIM CONV AIM not applied 4.9% (517,874/10,580,372) not applied not applied 8.41% (2132,532) not applied TRAV TRAJ TRBJ TRAJ not applied 8.41% (2132,532) not applied TRAV TRAJ TRBJ TRAJ not applied BV20-1 (98.59%) BJ1-3 (99.53%) not applied	AIM CONV AIM CCC not applied 4.9% (517,874/10,580,372) not applied 10.14% (948,772) not applied 8.41% (213/2,532) not applied 2.3% (12,132,132) TRAV TRAJ TRBV TRAV TRAJ not applied BV20-1 (98.59%) BJ1-3 (99.53%) not applied BV20-1 (98.48%)	De Novo "SARD" (11-mer) E1603 E1632 AIM CONV AIM CONV not applied 4.9% (517,874/10,580,372) not applied 10.14% (948,733/9,348,647) not applied 8.41% (2132,532) not applied 2.3% (132/5,764) TRAV TRAJ TRBV TRBJ TRAV TRBJ not applied BV20-1 (98.59%) BJ1-3 (99.53%) not applied BV20-1 (98.48%) BJ1 (89.39%)	De Novo "SARD" (11-mer) E1603 E1632 E1632 AIM CONV AIM CONV AI not applied 4.9% (517,874/10,580,372) not applied 10.14% (948,733/9,348,647) not applied not applied 8.41% (213/2,532) not applied 2.3% (132/5,764) not ap TRAV TRAJ TRBJ TRAV TRAJ TRAV TRAJ TRAV not applied BV20-1 (98.59%) BJ1-3 (99.53%) not applied BV20-1 (98.48%) BJ1 (89.39%) not applied	De Novo "SARD" (11-mer) E1603 E1632 I AIM CONV AIM CONV AIM not applied 4.9% (517,874/10,580,372) not applied 10.14% (948,733/9,348,647) not applied not applied 8.41% (213/2,532) not applied 2.3% (132/5,764) not applied TRAV TRAJ TRBJ TRAV TRAJ TRAV TRAJ not applied BV20-1 (98.59%) BJ1-3 (99.53%) not applied BV20-1 (98.48%) BJ1 (89.39%) not applied	De Novo "SARD" (11-mer) E1603 E1655 AIM CONV AIM CONV AIM COS not applied 4.9% (517,874/10,580,372) not applied 10.14% (948,733/9,348,647) not applied 0.012% (666 not applied 8.41% (2132,532) not applied 2.3% (132/5,764) not applied 1.4% (7 TRAV TRAJ TRBV TRAJ TRAV TRAJ TRAJ TRAJ TRBV TRAJ TRBV 1014(98,48%) B1(89,3%) not applied 8V20-1 (98.48%) B1(189.39%) not applied BV20-1 (98.48%) B1(189.39%) not applied BV20-1 (98.48%) B1(100%) 100%)